Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study.

Autor:	Meijide Míguez H; Department of Internal Medicine, Hospital Quironsalud A Coruña, A Coruña, Spain., Montes García I; Executive Director, Residencia Dulcinea, Grupo Quirónsalud, Alcázar de San Juan, Ciudad Real, Spain., Ochando Gómez M; Technical Director of Clinical Laboratory, Health Diagnostic, Grupo Quironsalud, Madrid, Spain., García Merino IM; Department of Research and Innovation, Grupo Quirónsalud, Madrid, Spain., Cano EL; Research Centre for Intelligent Information Technologies (CETINIA-DSLAB), Rey Juan Carlos University, Móstoles, Spain; Quantitative Methods and Socio-economic Development Group, Institute for Regional Development (IDR), University of Castilla-La Mancha (UCLM), Albacete, Spain., De La Torre A; Scientific Director, Clinica Imbanaco, Grupo Quironsalud, Cali, Valle del Cauca, Colombia. Electronic address: alejandro.delatorre@imbanaco.com.co.
Jazyk:	angličtina
Zdroj:	Revista espanola de geriatria y gerontologia [Rev Esp Geriatr Gerontol] 2023 May-Jun; Vol. 58 (3), pp. 125-133. Date of Electronic Publication: 2023 Mar 06.
DOI:	10.1016/j.regg.2023.02.009
Abstrakt:	Introduction: BNT162b2 (BioNTech and Pfizer) is a nucleoside-modified mRNA vaccine that provides protection against SARS-CoV-2 infection and is generally well tolerated. However, data about its efficacy, immunogenicity and safety in people of old age or with underlying chronic conditions are scarce. Purpose: To describe BNT162b2 (BioNTech and Pfizer) COVID-19 vaccine immunogenicity, effectiveness and reactogenicity after complete vaccination (two doses), and immunogenicity and reactogenicity after one booster, in elders residing in nursing homes (NH) and healthy NH workers in real-life conditions. Methods: Observational, ambispective, multicenter study. Older adults and health workers were recruited from three nursing homes of a private hospital corporation located in three Spanish cities. The primary vaccination was carried out between January and March 2021. The follow-up was 13 months. Humoral immunity, adverse events, SARS-CoV-2 infections, hospitalizations and deaths were evaluated. Cellular immunity was assessed in a participant subset. Results: A total of 181 residents (mean age 84.1 years; 89.9% females, Charlson index ≥2: 45%) and 148 members of staff (mean age 45.2 years; 70.2% females) were surveyed (n:329). After primary vaccination of 327 participants, vaccine response in both groups was similar; ≈70% of participants, regardless of the group, had an antibody titer above the cut-off considered currently protective (260BAU/ml). This proportion increased significantly to ≈ 98% after the booster (p<0.0001 in both groups). Immunogenicity was largely determined by a prior history of COVID-19 infection. Twenty residents and 3 workers were tested for cellular immunity. There was evidence of cellular immunity after primary vaccination and after booster. During the study, one resident was hospitalized for SARS-CoV-2. No SARS-CoV-2-related deaths were reported and most adverse events were mild. Conclusions: Our results suggest that the BNT162b2 mRNA COVID-19 vaccine is immunogenic, effective and safe in elderly NH residents with underlying chronic conditions. (Copyright © 2023 SEGG. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu